Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumorsTANIOKA, M; NOKIHARA, H; TAMURA, T et al.Cancer chemotherapy and pharmacology. 2011, Vol 68, Num 2, pp 505-511, issn 0344-5704, 7 p.Article

Monocyte chemoattractant protein-1 gene modification of multidrug-resistant human lung cancer enhances antimetastatic effect of therapy with anti-P-glycoprotein antibody in SCID miceNOKIHARA, H; NISHIOKA, Y; YANO, S et al.International journal of cancer. 1999, Vol 80, Num 5, pp 773-780, issn 0020-7136Article

Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4)MURAKAMI, H; TAMURA, T; YAMAMOTO, N et al.Cancer chemotherapy and pharmacology. 2012, Vol 69, Num 4, pp 891-899, issn 0344-5704, 9 p.Article

Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancerGOTO, K; SEKINE, I; TAMURA, T et al.British journal of cancer. 2004, Vol 91, Num 4, pp 659-665, issn 0007-0920, 7 p.Article

Heterogeneity of multiorgan metastases of human lung cancer cells genetically engineered to produce cytokines and reversal using chimeric monoclonal antibodies in natural killer cell-depleted severe combined immunodeficient miceSONE, S; YANO, S; HANIBUCHI, M et al.Cancer chemotherapy and pharmacology. 1999, Vol 43, pp S26-S31, issn 0344-5704, SUPConference Paper

Characteristics and outcomes of patients with advanced non-small-cell lung cancer who declined to participate in randomised clinical chemotherapy trialsLANAI, C; NOKIHARA, H; YAMAMOTO, S et al.British journal of cancer. 2009, Vol 100, Num 7, pp 1037-1042, issn 0007-0920, 6 p.Article

Therapeutic efficacy of a new topoisomerase I and II inhibitor TAS-103, against both P-glycoprotein-expressing and -nonexpressing drug-resistant human small-cell lung cancerPARAJULI, P; YANO, S; NISHIOKA, Y et al.Oncology research. 1999, Vol 11, Num 5, pp 219-224, issn 0965-0407Article

Combined therapy with anti-p-glycoprotein antibody and macrophage colony-stimulating factor gene transduction for multiorgan metastases of multidrug-resistant human small cell lung cancer in NK cell-depleted scid miceYANO, S; HANIBUCHI, M; NISHIOKA, Y et al.International journal of cancer. 1999, Vol 82, Num 1, pp 105-111, issn 0020-7136Article

A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patientsOHE, Y; NIHO, S; WATANABE, K et al.Annals of oncology. 2004, Vol 15, Num 1, pp 45-50, issn 0923-7534, 6 p.Article

Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinomaSEKINE, I; NOKIHARA, H; HORIIKE, A et al.British journal of cancer. 2004, Vol 90, Num 6, pp 1125-1128, issn 0007-0920, 4 p.Article

Model of malignant pleural effusion of human lung adenocarcinoma in SCID miceYANO, S; NOKIHARA, H; HANIBUCHI, M et al.Oncology research. 1997, Vol 9, Num 11-12, pp 573-579, issn 0965-0407Article

Systemic chemotherapy alters interleukin-1β and its receptor antagonist production by human alveolar macrophages in lung cancer patientsHAKU, T; YANAGAWA, H; OHMOTO, Y et al.Oncology research. 1996, Vol 8, Num 12, pp 519-526, issn 0965-0407Article